These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 29605841)

  • 1. Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
    Nash P; McInnes IB; Mease PJ; Thom H; Hunger M; Karabis A; Gandhi K; Mpofu S; Jugl SM
    Rheumatol Ther; 2018 Jun; 5(1):99-122. PubMed ID: 29605841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.
    Strand V; Betts KA; Mittal M; Song J; Skup M; Joshi A
    Rheumatol Ther; 2017 Dec; 4(2):349-362. PubMed ID: 28762213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.
    Mease P; Choy E; Nash P; Kalyvas C; Hunger M; Pricop L; Gandhi KK; Jugl SM; Thom H
    Eur J Rheumatol; 2019 Jul; 6(3):113-121. PubMed ID: 31364979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.
    Maksymowych WP; Strand V; Nash P; Yazici Y; Thom H; Hunger M; Kalyvas C; Gandhi KK; Porter B; Jugl SM
    Eur J Rheumatol; 2018 Dec; 5(4):216-223. PubMed ID: 30388073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.
    Strand V; McInnes I; Mease P; Nash P; Thom H; Kalyvas C; Hunger M; Gandhi K; Pricop L; Jugl S; Choy E
    J Comp Eff Res; 2019 May; 8(7):497-510. PubMed ID: 30806520
    [No Abstract]   [Full Text] [Related]  

  • 8. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease.
    Gisondi P; Geat D; Maurelli M; Degli Esposti L; Bellinato F; Girolomoni G
    Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Kivitz AJ; Nash P; Rahman P; Rech J; Conaghan PG; Kirkham B; Navarra S; Belsare AD; Delicha EM; Pricop L
    Lancet Rheumatol; 2020 Apr; 2(4):e227-e235. PubMed ID: 38268157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ; Warren RB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; McInnes IB
    Rheumatol Ther; 2024 Jun; 11(3):817-828. PubMed ID: 38446397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
    Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
    Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
    Kaeley GS; Schett G; Conaghan PG; McGonagle D; Behrens F; Goupille P; Gaillez C; Parikh B; Bakewell C
    Rheumatology (Oxford); 2024 Jan; 63(1):41-49. PubMed ID: 37097894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens.
    Zhang KL; Hou SY; Wu D
    Clinics (Sao Paulo); 2021; 76():e2820. PubMed ID: 34614111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.